Scientific Program

*It is based on the local time of Seoul, Korea. (UTC/GMT +9:00) Updated as of September 8

* [KOR] = Sessions in Korean

Thursday, November 11

Keynote Lecture

Date & Time 11/11(Thu) 08:10-08:40 Place Room A
  • ·
  • Progress in targeting KRAS directly

    Frank McCormick (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA)

Educational Session: New insights for clinical trials in IO era

Date & Time 11/11(Thu) 09:00-10:40 Place Room A
  • ·
  • Immune approaches to cancer therapy: Building on lessons from checkpoint blockade

    Jedd D. Wolchok (Memorial Sloan Kettering Cancer Center, New York, NY, USA)

  • ·
  • Next generation immunotherapy beyond anti-PD-1 and CTLA4

    Myung-Ju Ahn (Sungkyunkwan University School of Medicine, Korea)

  • ·
  • Academic clinical trials of CAR T cell therapy for cancer

    Marcela V. Maus (Harvard Medical School, Boston, MA, USA)

  • ·
  • Immunotherapy with chemotherapy or PARP inhibitors : A game changer?

    Seock-Ah Im (Seoul National University College of Medicine, Korea)

Session 1: Proteogenomics

Date & Time 11/11(Thu) 11:00-12:40 Place Room A
  • ·
  • Proteomic characterization of the RAS secretome

    Peter K. Jackson (Stanford University, Stanford, CA, USA)

  • ·
  • Mobilization of LINE-1 retrotransposons in colorectal epithelium

    Young Seok Ju (Korea Advanced Institute of Science and Technology, Korea)

  • ·
  • Systematic elucidation and pharmacological targeting of non-oncogene dependencies in single cells

    Andrea Califano (Columbia University, New York, NY, USA)

  • ·
  • Gastric cancer proteogenomics

    Daehee Hwang (Seoul National University College of Natural Sciences, Korea)

KCA Symposium 1: Neoadjuvant Treatment and Conversion Surgery [KOR]

Date & Time 11/11(Thu) 15:50-17:05 Place Room A
  • ·
  • Current issues with neoadjuvant chemotherapy and surgery in breast cancer

    Jeong Eon Lee (Sungkyunkwan University School of Medicine, Korea)

  • ·
  • Current issues in neoadjuvant therapy of lung cancer

    Kwon Joong Na (Seoul National University Hospital, Korea)

  • ·
  • Surgery after neoadjuvant therapy for locally advanced or borderline resectable pancreatic cancer

    Ki-byung Song (University of Ulsan College of Medicine, Korea)

KCA Symposium 2: AI in Cancer Research [KOR]

Date & Time 11/11(Thu) 15:50-17:05 Place Room B
  • ·
  • Medical image analysis using deep learning

    Sang Hyun Park (Daegu Gyeongbuk Institute of Science & Technology, Korea)

  • ·
  • AI application in cancer imaging

    Joon Beom Seo (University of Ulsan College of Medicine, Korea)

  • ·
  • AI application in pathology

    Seokhwi Kim (Ajou University School of Medicine, Korea)

Satellite Symposium 01 (ONO/BMS)

Date & Time 11/11(Thu) 13:10-14:10 Place Room A
  • ·
  • Transforming the treatment paradigm in GC/GEJ/EAC 1L: Nivolumab + Chemotherapy

    Sook-ryun Park (University of Ulsan College of Medicine, Korea)

  • ·
  • Innovative treatment of aRCC 1L with superior long-term efficacy and tolerability: Nivolumab + Ipilimumab

    Inkeun Park (Gachon University College of Medicine, Korea)

Satellite Symposium 02 (MSD)

Date & Time 11/11(Thu) 13:10-13:30 Place Room B
  • ·
  • Pembrolizumab+Lenvatinib: the promising combination treatment for advanced solid tumors

    Min Hwan Kim (Yonsei University College of Medicine, Korea)

Satellite Symposium 03 (Illumina)

Date & Time 11/11(Thu) 13:30-13:50 Place Room B
  • ·
  • Enable Comprehensive Genomic Profiling from liquid biopsysolid tumors

    Ja-Hyun Jang (Samsung Medical Center, Korea)

Satellite Symposium 04 (Bayer)

Date & Time 11/11(Thu) 13:50-14:10 Place Room B
  • ·
  • Larotrectinib – a new selective TRK inhibitor for NTRK fusion-positive cancer patients

    Dae Ho Lee (University of Ulsan College of Medicine, Korea)

Proffered Papers Session

Friday, November 12

Waun Ki Hong Memorial Lecture

Date & Time 11/12(Fri) 08:00-08:30 Place Room A
  • ·
  • Tumor Microenvironment: Challenges and Opportunities

    Gou Young Koh (Korea Advanced Institute of Science and Technology, Korea)

Session 2: Preclinical Models

Date & Time 11/12(Fri) 08:50-10:30 Place Room A
  • ·
  • Using a cancer dependency map

    William C. Hahn (Dana-Farber Cancer Institute, Boston, MA, USA)

  • ·
  • Creation of tumor assembloids recapitulating epithelial-stromal interaction in human cancers: Role of Foxa1-Hedgehog-Bmp axis in tumor plasticity

    Kunyoo Shin (Pohang University of Science and Technology, Korea)

  • ·
  • Organoid modeling of lung disease and lung cancer

    Carla F. Kim (Boston Children’s Hospital, Boston, MA, USA)

  • ·
  • The cooperation of YAP and AP-1 in ductal cell-derived pancreatic cancer development

    Dae-Sik Lim (Korea Advanced Institute of Science and Technology, Korea)

Session 3: Precision Medicine in Immuno-Oncology

Date & Time 11/12(Fri) 08:50-10:30 Place Room B
  • ·
  • Updates and advances in personalized cancer vaccines

    Catherine J. Wu (Dana-Farber Cancer Institute, Boston, MA, USA)

  • ·
  • TCR-seq analysis in anti-PD-1-treated patients

    Eui-Cheol Shin (Korea Advanced Institute of Science and Technology, Korea)

  • ·
  • Defining the actionable genome

    David B. Solit (Memorial Sloan Kettering Cancer Center, New York, NY, USA)

  • ·
  • Updates in gastric cancer immunogenomics

    Jeeyun Lee (Sungkyunkwan University School of Medicine, Korea)

Session 4: Targeting the RAS Pathway

Date & Time 11/12(Fri) 10:50-12:30 Place Room A
  • ·
  • Acquired resistance to KRAS G12C Inhibition

    Andrew J. Aguirre (Dana-Farber Cancer Institute, Boston, MA, USA)

  • ·
  • Resistance mechanism and overcome strategy to RAF inhibitor belvarafenib

    Tae Won Kim (University of Ulsan College of Medicine, Korea)

  • ·
  • Discovering and deploying chemical strategies to drug KRAS: The formerly undruggable oncogene

    Kevan Shokat (University of California San Francisco, San Francisco, CA, USA)

  • ·
  • Novel route to control KRAS-driven cancers

    Sunghoon Kim (Yonsei University College of Pharmacy, Korea)

Session 5: Novel Discoveries in Drug Screening

Date & Time 11/12(Fri) 10:50-12:30 Place Room B
  • ·
  • The discovery of context specific paralog dependence in cancer through combinatorial CRISPR screens

    William R. Sellers (Broad Institute of MIT and Harvard, Cambridge, MA, USA)

  • ·
  • Harnessing tumor bioenergetics in de novo target discovery for refractory SEM subtype cancer : a new concept proposition

    Jae-Ho Cheong (Yonsei University College of Medicine, Korea)

  • ·
  • Accelerating inhibitor discovery to functionally annotate deubiquitinating enzymes

    Sara J. Buhrlage (Dana-Farber Cancer Institute, Boston, MA, USA)

  • ·
  • Microfabricated assays to investigate tumor microenvironment

    Seok Chung (Korea University, Korea)

KCA Symposium 3: Practical Issues in AYA Oncology [KOR]

Date & Time 11/12(Fri) 14:30-15:30 Place Room A
  • ·
  • NCCN clinical practice guideline of adolescent and young adult oncology

    Yeon-Jung Lim (Chungnam National University College of Medicine, Korea)

  • ·
  • Extracranial germ cell tumors in adolescents and young adults

    Seung Min Hahn (Yonsei University College of Medicine, Korea)

  • ·
  • Adenocarcinoma in adolescents and young adults

    Hee-Beom Yang (Seoul National University Bundang Hospital, Korea)

KCA Symposium 4: Next-generation Targeted Therapy [KOR]

Date & Time 11/12(Fri) 14:30-15:30 Place Room B
  • ·
  • Recent advance in the development of novel, selective and potent FGFR inhibitors

    Hee Jun Kim (Chung-Ang University College of Medicine, Korea)

  • ·
  • HER2-targeted therapies - a role beyond breast and gastric cancer

    Miso Kim (Seoul National University College of Medicine, Korea)

  • ·
  • Inhibitors of MET and RET in non-small cell lung cancer (NSCLC)

    Min Hee Hong (Yonsei University College of Medicine, Korea)

KCA Symposium 5: Precision Medicine Based on Molecular Tumor Board [KOR]

Date & Time 11/12(Fri) 15:50-17:05 Place Room A
  • ·
  • Experience of molecular tumor board in sponsor-initiated trial

    Jeong-Eun Kim (University of Ulsan College of Medicine, Korea)

  • ·
  • Making molecular profiling guided therapy a reality for Korean patients: KOSMOS adventure

    Jee Hyun Kim (Seoul National University College of Medicine, Korea)

  • ·
  • Nationwide precision medicine to accelerate targeted cancer therapies

    Soohyeon Lee (Korea University College of Medicine, Korea)

KCA Symposium 6: Clinical Trials in Radiation Oncology [KOR]

Date & Time 11/12(Fri) 15:50-17:05 Place Room B
  • ·
  • RTOG 1119: Phase II randomized study of whole brain radiotherapy/stereotactic radiosurgery with concurrent lapatinib patients with brain metastases from HER2-positive breast cancer
    - a collaborative study of NRG Oncology and KROG

    In Ah Kim (Seoul National University College of Medicine, Korea)

  • ·
  • Result and lesson from KROG 08-06 trial

    Yong Bae Kim (Yonsei University College of Medicine, Korea)

  • ·
  • Proton Beam Radiotherapy (PBT) vs Radiofrequency Ablation (RFA) treatment for recurrent hepatocellular carcinoma: A randomized controlled phase 3 non-inferiority APROH trial

    Tae Hyun Kim (National Cancer Center, Korea)

Satellite Symposium 05 (Pfizer)

Date & Time 11/12(Fri) 13:10-13:30 Place Room A
  • ·
  • Optimizing clinical outcomes for Asian patients with EGFR mutation-positive NSCLC

    Yun-Gyoo Lee (Kangbuk Samsung Hospital, Korea)

Satellite Symposium 06 (Lilly)

Date & Time 11/12(Fri) 13:10-13:30 Place Room B
  • ·
  • Optimizing treatment for HR+, HER2- metastatic breast cancer patients

    Joo Hyuk Sohn (Yonsei University College of Medicine, Korea)

Satellite Symposium 07 (AstraZeneca)

Date & Time 11/12(Fri) 13:30-13:50 Place Room A
  • ·
  • Why PACIFIC regimen in UR St.III NSCLC treatment? – evidence from PACIFIC 5Y OS data

    Hyun Ae Jung (Samsung Medical Center, Korea)

Satellite Symposium 08 (Roche)

Date & Time 11/12(Fri) 13:30-13:50 Place Room B
  • ·
  • Tumor agnostic therapies toward precision medicine era

    Byoung Chul Cho (Yonsei University College of Medicine, Korea)

Satellite Symposium 09 (Yuhan)

Date & Time 11/12(Fri) 13:50-14:10 Place Room A
  • ·
  • Treatment for advanced EGFR T790M-positive NSCLC

    Tae Min Kim (Seoul National University College of Medicine, Korea)

Satellite Symposium 10 (Servier)

Date & Time 11/12(Fri) 13:50-14:10 Place Room B
  • ·
  • New hope for metastatic pancreatic cancer with liposomal irinotecan

    Jaekyung Cheon (CHA University School of Medicine, Korea)